SOUTH SAN FRANCISCO, Calif., May 21, 2024 Pliant Therapeutics, Inc. , a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment.
SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader.
Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company will present four scientific posters at the upcoming 2024 American Thoracic Society (ATS) International Conference, takin
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Pulmonary Fibrosis Foundation Urges COVID-19 Vaccination In Letter To Patients
December 28, 2020 GMT
The Pulmonary Fibrosis Foundation s Medical and Scientific Advisory Board is recommending COVID-19 vaccination for individuals with pulmonary fibrosis.
The Pulmonary Fibrosis Foundation s Medical and Scientific Advisory Board is recommending COVID-19 vaccination for individuals with pulmonary fibrosis.
CHICAGO, Dec. 28, 2020 /PRNewswire/ The Pulmonary Fibrosis Foundation (PFF) is encouraging COVID-19 vaccination for individuals with pulmonary fibrosis, a progressive and debilitating lung disease affecting more than 200,000 Americans.
In a letter to the PF community, the PFF Medical & Scientific Advisory Board strongly recommends vaccination, along with the safe practices of physical distancing, hand washing, and face coverings, to help prevent COVID-19 illness.